Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
Top Cited Papers
- 3 May 2007
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 108 (2) , 241-250
- https://doi.org/10.1007/s10549-007-9591-y
Abstract
Genexol-PM is a novel Cremophor EL-free polymeric micelle formulation of paclitaxel. This single arm, multicenter phase II study was designed to evaluate the efficacy and safety of Genexol-PM in patients with histologically confirmed metastatic breast cancer (MBC). Forty-one women received Genexol-PM by intravenous infusion at 300 mg/m2 over 3 h every 3 weeks without premedication until disease progression or intolerability. A total of 331 chemotherapy cycles were administered, with a median of 8 cycles per patient (range, 1–16). Overall response rate was 58.5% (95% CI: 43.5–72.3) with 5 complete responses and 19 partial responses. Thirty-seven patients who received Genexol-PM as a first-line therapy for their metastatic disease showed a response rate of 59.5% (95% CI: 43.5–73.7), and two responses were reported in four patients treated in the second-line setting for their metastatic disease. The median time to progression (TTP) for all patients was 9.0 months (range, 1.0–17.0+ months). Grade 3 non-hematologic toxicities included sensory peripheral neuropathy (51.2%), and myalgia (2.4%). Eight patients (19.5%) experienced hypersensitivity reactions, with grade 3 in two patients. Hematologic toxicities were grade 3 and 4 neutropenia (51.2 and 17.1%, respectively), and grade 1 and 2 thrombocytopenia (22.0%). Notably, no febrile neutropenia was observed. Genexol-PM appears a promising new paclitaxel in view of significant efficacies. Further trials with different dosing schedules, durations of delivery, or in combination with other drugs are warranted.Keywords
This publication has 36 references indexed in Scilit:
- Peripheral neuropathy: A persisting challenge in paclitaxel-based regimesEuropean Journal Of Cancer, 2006
- Novel formulations of taxanes: a review. Old wine in a new bottle?Annals of Oncology, 2005
- Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced MalignanciesClinical Cancer Research, 2004
- Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimensBritish Journal of Cancer, 2004
- Use and abuse of taxanes in the management of metastatic breast cancerEuropean Journal Of Cancer, 2003
- Prophylaxis for Paclitaxel Hypersensitivity ReactionsAnnals of Pharmacotherapy, 2001
- Cremophor ELEuropean Journal Of Cancer, 2001
- In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacyJournal of Controlled Release, 2001
- The clinical effects of plasticizers, antioxidants, and other contaminants in medical polyvinylchloride tubing during respiratory and non-respiratory exposureClinica Chimica Acta; International Journal of Clinical Chemistry, 2001
- Phthalate Esters and Their Effect on the LiverHepatology, 1984